Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk.

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and nutrition guidance," Hims & Hers said. 

"We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications," Hims & Hers CEO Andrew Dudum said in a statement. "We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future." 

Shares of Hims & Hers jumped 25% on the news.

It will carry a monthly $599 starting price tag. Novo Nordisk’s NovoCare Pharmacy, a direct-to-patient online pharmacy geared toward cash-paying Wegovy patients that went live last month, will be directly available through the telehealth company’s platform as part of the partnership.

Hims & Hers and Novo Nordisk will launch the bundle on the telehealth company’s platform this week. 

It "builds on Hims & Hers’ existing suite of weight loss solutions and provides access to all dose strengths of Wegovy in a high-quality pen for self-pay patients," Hims & Hers said. 

In addition to the bundle, Hims & Hers said the two companies are in the process of devising a roadmap that combines the Danish drugmaker’s "innovative treatments" with the telehealth platform’s "ability to scale access to quality care."

Two other telehealth companies, Ro and Life MD, similarly unveiled partnerships with Novo Nordisk on Tuesday that will involve integrating NovoCare Pharmacy into their platforms and offering Wegovy. 

Wegovy is one of several GLP-1 medications that have become extremely popular for weight loss in recent years, along with Novo's Ozempic and Eli Lilly's Zepbound and Mounjaro.